½ÃÀ庸°í¼­
»óǰÄÚµå
1461294

ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå : Åõ¿©°æ·Îº°, ÀûÀÀÁõº°, À¯Åëä³Îº°, Áö¿ªº° ½ÃÀå ÇöȲ

Cosentyx Drug Market, By Route of Administration, By Indication, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÄÚ¼¾Æ½½º ÀǾàǰ ¼¼°è ½ÃÀåÀº 2024³â 53¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 7.3% ¼ºÀåÇÏ¿© 2031³â¿¡´Â 87¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼³»¿ë
±âÁس⵵ 2023³â 2023³â/2024³â ½ÃÀå ±Ô¸ð 532¾ï 2,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
2023³â/2024-2030³â/2031³â CAGR: 7.30% 2030/2031³â ¿¹ÃøÄ¡ 87¾ï 4,000¸¸ ´Þ·¯
ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Cosentyx Drug Market-IMG1

ÄÚ¼¾Æ½½º(¼ººÐ¸í: secukinumab)´Â È£Áß±¸ÀÇ À̵¿°ú Ȱ¼ºÈ­¿¡ °ü¿©ÇÏ´Â ¿°Áõ¼º »çÀÌÅäÄ«ÀÎÀÎ ÀÎÅÍ·çŲ-17A(IL-17A)¿¡ ¼±ÅÃÀûÀ¸·Î °áÇÕÇÏ¿© À̸¦ ¾ïÁ¦ÇÏ´Â Àΰ£Çü ´ÜÀÏŬ·ÐÇ×üÀÔ´Ï´Ù. 2015³â Ãâ½ÃµÈ ÄÚ¼¾Æ½½º´Â Àü ¼¼°è 80¿© °³±¹¿¡¼­ Áߵ¿¡¼­ ÁßÁõÀÇ ÆÇ»ó °Ç¼±, °üÀý¿°¼º °Ç¼±, °­Á÷¼º ôÃß¿° Ä¡·áÁ¦·Î ½ÂÀεƽÀ´Ï´Ù. Ãâ½Ã ÈÄ ¸î³â¸¸¿¡ ³ôÀº È¿´É°ú ¿ì¼öÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ·Î Å« ½ÃÀå Á¡À¯À²À» È®º¸ÇÏ¸ç º£½ºÆ®¼¿·¯·Î ÀÚ¸®¸Å±èÇß½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

°Ç¼±, °Ç¼±¼º °üÀý¿°, °­Á÷¼º ôÃß¿°°ú °°Àº ¸é¿ª ¸Å°³ ¿°Áõ¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ¼¼°è ÄÚ¼¾Æ½½º ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû »ý¹°ÇÐÀû Á¦Á¦ÀÇ °¡¿ë¼º°ú ±âÁ¸ Ä¡·á¹ý ´ëºñ ¿ì¼öÇÑ È¿´É¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î È¿´É°ú È¿°ú¸¦ °¡Áø ÆÄÀÌÇÁ¶óÀÎÀÇ Áö¼ÓÀûÀÎ È®ÀåÀ¸·Î ´ë»ó ȯÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª 2027³â±îÁö ÁÖ¿ä Áö¿ª¿¡¼­ÀÇ Æ¯Çã ¸¸·á¿Í IL-17À» Ç¥ÀûÀ¸·Î ÇÏ´Â ´Ù¾çÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ÁøÀÔÀº ÄÚ¼¾Æ½½ºÀÇ ¼ºÀåÀ» ¾î´À Á¤µµ ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ Áö¸®Àû È®Àå°ú »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛ °³¹ßÀº Àå±âÀûÀ¸·Î ¼öÀÍÀ» Áö¼ÓÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© 2024-2031³â ¿¹Ãø ±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÏ´Â ÄÚ¼¾Æ½ ÀǾàǰ ¼¼°è ½ÃÀåÀ» ½ÉÃþ ºÐ¼®ÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µî ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÄÚ¼¾Æ½ ÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • À̹ø Á¶»ç ´ë»óÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Novartis AG°¡ Æ÷ÇԵ˴ϴÙ.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ÄÚ¼¾Æ½ ÀǾàǰ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÄÚ¼¾Æ½ ÀǾàǰ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå °³¿ä

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ½ÃÀå ±âȸ ¸Ê

Á¦3Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´, Àμö, Çù¾÷ ½Ã³ª¸®¿À
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • °¡°Ý ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ¿ªÇÐ
  • ¹Ì±¹ ½ºÀ§Ä¡ ºñÀ² ºÐ¼®
  • ȯ±Þ ½Ã³ª¸®¿À
  • ÀÛ¿ë±âÀü
  • Á¦Á¶´É·Â

Á¦4Àå ¼¼°èÀÇ ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå, Åõ¿© °æ·Îº°, 2019³â-2031³â

  • ÇÇÇÏ ÁÖ»ç
  • Á¤¸Æ³» ÁÖÀÔ

Á¦5Àå ¼¼°èÀÇ ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå, ÀûÀÀÁõº°, 2019³â-2031³â

  • È­³ó¼º ÇѼ±¿°
  • °Ç¼±¼º °üÀý¿°
  • °­Á÷¼º ôÃß¿°
  • ½É»ó¼º °Ç¼±
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2031³â

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦7Àå ¼¼°èÀÇ ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå, Áö¿ªº°, 2019³â-2031³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • °ÉÇÁÇù·ÂȸÀÇ
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«

Á¦8Àå ±â¾÷ °³¿ä - ¼¼°èÀÇ ÄÚ¼¾Æ½½º ÀǾàǰ ½ÃÀå

  • Novartis AG
    • ±â¾÷ °³¿ä
    • Á¦Ç°/¼­ºñ½º Æ÷Æ®Æú¸®¿À
    • À繫 ½ÇÀû
    • ÃÖ±Ù °³¹ß/°»½Å
    • Àü·« °³¿ä

Á¦9Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
LSH 24.05.16

Global cosentyx drug market is estimated to be valued at USD 5.32 Bn in 2024, and is expected to reach USD 8.74 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 5.32 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 7.30% 2030/2031 Value Projection: US$ 8.74 Bn
Cosentyx Drug Market Share (%), By Region, 2024
Cosentyx Drug Market - IMG1

Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds and inhibits interleukin-17A (IL-17A), a proinflammatory cytokine that is involved in neutrophil recruitment and activation. Launched in 2015 by Novartis, Cosentyx is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in over 80 countries worldwide. Within the first few years of its launch, it has established itself as one of the top selling drugs, capturing a sizable market share due to its high efficacy and favorable safety profile.

Market Dynamics:

Global cosentyx drug market growth is driven by rising prevalence of immune-mediated inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Growing awareness about the availability of targeted biologic drugs and their superior efficacy over conventional therapies are driving the market growth. The continuous pipeline expansion through new indications and strengths is expanding the eligible patient pool. However, the drug's patent expiration in major regions by 2027, combined with the market entry of different IL-17 targeting biosimilars, may impede the growth of Cosentyx to some extent. The geographical expansion into emerging markets and development of novel drug delivery systems with improved formulations offer lucrative opportunities for sustained revenues over the long-run.

Key Features of the Study:

  • This report provides an in-depth analysis of the global cosentyx drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cosentyx drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • The key companies covered as a part of this study include Novartis AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global cosentyx drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cosentyx drug market.

Detailed Segmentation:

  • Route of Administration:
    • Subcutaneous injection
    • Intravenous infusion
  • Indication:
    • Hidradenitis suppurativa
    • Psoriatic arthritis
    • Ankylosing spondylitis
    • Plaque Psoriasis
    • Others
  • Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Novartis AG

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Indication
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
    • Market Scenario - Conservative, Like, Opportunistic
  • Market Opportunity Map

3. Key Insights

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Pest Analysis
  • Porters Analysis
  • Merger, Acquisition and Collaboration Scenario
  • Regulatory Scenario
  • Pricing Analysis
  • COVID-19 Impact Analysis
  • Pipeline Analysis
  • Epidemiology
  • Switch Rate Analysis in U.S.
  • Reimbursement Scenario
  • Mode of Action
  • Manufacturing Capacities

4. Global Cosentyx Drug Market, By Route of Administration, 2019 - 2031, (US$ Billion)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031
    • Market Y-o-Y Growth Comparison (%), 2019 - 2031
    • Segment Trends
  • Subcutaneous injection, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Intravenous infusion, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)

5. Global Cosentyx Drug Market, By Indication, 2019 - 2031, (US$ Billion)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031
    • Market Y-o-Y Growth Comparison (%), 2019 - 2031
    • Segment Trends
  • Hidradenitis suppurativa, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Psoriatic arthritis, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Ankylosing spondylitis, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Plaque Psoriasis, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Others, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)

6. Global Cosentyx Drug Market, By Distribution Channel, 2019 - 2031, (US$ Billion)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031
    • Market Y-o-Y Growth Comparison (%), 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Online Pharmacies, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)
  • Retail Pharmacies, 2019 - 2031 (US$ Billion)
    • Introduction
    • Market Size and Forecast, 2019 - 2031, (US$ Billion)

7. Global Cosentyx Drug Market, By Region, 2019 - 2031, (US$ Billion)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, (US$ Billion)
    • Market Y-o-Y Growth Comparison (%), 2019 - 2031, (US$ Billion)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
  • GCC
  • Israel
  • Rest of The Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Indication, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, (US$ Billion)
  • South Africa
  • North Africa
  • Central Africa

8. Company Profiles - Global Cosentyx Drug Market

  • Novartis AG
    • Company Overview
    • Product/Service Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategic Overview

9. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦